Characteristics and outcomes of patients with CML in first chronic phase undergoing NST from fully matched donors
| Unique patient no. . | Age, y . | Sex . | Donor's relationship to patient . | Interval from diagnosis to NST, mo . | Acute GVHD* . | Chronic GVHD4* . | ||
|---|---|---|---|---|---|---|---|---|
| Recipient . | Donor . | +CSP . | −CSP . | |||||
| 1031 | 50 | M | M | Sibling | 19 | 0 | II | Mild |
| 1053† | 57 | M | M | Sibling | 7 | 0 | II | 0 |
| 1119†,‡ | 3 | M | M | Father | 15 | 0 | IV | Severe→mild |
| 1135† | 34 | F | F | Sibling | 32 | 0 | IV | 0 |
| 1137† | 39 | M | M | Sibling | 3 | 0 | 0 | Mild |
| 1143† | 37 | M | F | Sibling | 5 | 0 | I | Mild |
| 1159 | 46 | M | M | Sibling | 9 | 0 | II | Moderate→resolved |
| 1176 | 48 | M | F | Sibling | 8 | II | NA | 0 |
| 1179 | 48 | F | M | MUD | 40 | II | NA | Mild |
| 1239 | 51 | M | F | Sibling | 6 | II | NA | Mild |
| 1286 | 26 | F | F | Sibling | 8 | II | NA | 0 |
| 1357 | 11 | M | M | MUD | 13 | III | NA | 0 |
| 1372 | 17 | M | F | MUD | 54 | IV | NA | Severe |
| 1379 | 45 | F | F | Sibling | 11 | IV | NA | Severe |
| 1384 | 20 | F | M | Sibling | 5 | III | NA | Severe |
| 1393 | 18 | M | F | MUD | 49 | II | NA | 0 |
| 1411 | 44 | F | F | Sibling | 3 | IV | NA | Moderate→mild |
| 1486 | 21 | F | F | Sibling | 13 | 0 | 0 | 0 |
| 1502 | 24 | F | M | Sibling | 7 | 0 | 0 | 0 |
| 1521 | 20 | F | F | MUD | 9 | II | NA | 0 |
| 1524 | 35 | M | M | Sibling | 4 | II | NA | Mild |
| 1575 | 25 | M | M | Sibling | 1 | I | 0 | Mild |
| 15761-153 | 25 | M | M | Sibling | 9 | 0 | 0 | 0 |
| 15771-153 | 63 | F | M | Sibling | 10 | 0 | 0 | 0 |
| Unique patient no. . | Age, y . | Sex . | Donor's relationship to patient . | Interval from diagnosis to NST, mo . | Acute GVHD* . | Chronic GVHD4* . | ||
|---|---|---|---|---|---|---|---|---|
| Recipient . | Donor . | +CSP . | −CSP . | |||||
| 1031 | 50 | M | M | Sibling | 19 | 0 | II | Mild |
| 1053† | 57 | M | M | Sibling | 7 | 0 | II | 0 |
| 1119†,‡ | 3 | M | M | Father | 15 | 0 | IV | Severe→mild |
| 1135† | 34 | F | F | Sibling | 32 | 0 | IV | 0 |
| 1137† | 39 | M | M | Sibling | 3 | 0 | 0 | Mild |
| 1143† | 37 | M | F | Sibling | 5 | 0 | I | Mild |
| 1159 | 46 | M | M | Sibling | 9 | 0 | II | Moderate→resolved |
| 1176 | 48 | M | F | Sibling | 8 | II | NA | 0 |
| 1179 | 48 | F | M | MUD | 40 | II | NA | Mild |
| 1239 | 51 | M | F | Sibling | 6 | II | NA | Mild |
| 1286 | 26 | F | F | Sibling | 8 | II | NA | 0 |
| 1357 | 11 | M | M | MUD | 13 | III | NA | 0 |
| 1372 | 17 | M | F | MUD | 54 | IV | NA | Severe |
| 1379 | 45 | F | F | Sibling | 11 | IV | NA | Severe |
| 1384 | 20 | F | M | Sibling | 5 | III | NA | Severe |
| 1393 | 18 | M | F | MUD | 49 | II | NA | 0 |
| 1411 | 44 | F | F | Sibling | 3 | IV | NA | Moderate→mild |
| 1486 | 21 | F | F | Sibling | 13 | 0 | 0 | 0 |
| 1502 | 24 | F | M | Sibling | 7 | 0 | 0 | 0 |
| 1521 | 20 | F | F | MUD | 9 | II | NA | 0 |
| 1524 | 35 | M | M | Sibling | 4 | II | NA | Mild |
| 1575 | 25 | M | M | Sibling | 1 | I | 0 | Mild |
| 15761-153 | 25 | M | M | Sibling | 9 | 0 | 0 | 0 |
| 15771-153 | 63 | F | M | Sibling | 10 | 0 | 0 | 0 |
Patient 1135 died of acute GVHD on day 116 after transplantation; patients 1372 and 1379 died of severe chronic GVHD on days 499 and 726 after transplantation, respectively.
CSP indicates cyclosporine A; and MUD, matched unrelated donor.
Graded according to International Bone Marrow Transplant Registry (IBMTR) severity indices.
Abrupt withdrawal of CSP.
Juvenile chronic myeloid leukemia.
Patients treated at the Souraski Medical Center.